Mycophenolic acid

Social determinants of health contribute to delayed and misdiagnosis of myasthenia gravis (MG), with high-risk factors including poor health literacy and housing insecurity. Common misdiagnoses for MG include stroke, COPD, and multiple sclerosis. Collaboration among healthcare systems, pharmaceutical companies, and advocacy groups is essential to address these disparities.

James Song, MD, FAAD, shared 4 clinical pearls at the Fall Clinical Dermatology Conference: treating severe alopecia areata with DCPC, refractory discoid lupus erythematosus with deucravacitinib, refractory dermatomyositis with upadacitinib, and acantholytic disorders with biologics and JAK inhibitors. He also discussed advancements in atopic dermatitis, prurigo nodularis, psoriasis, and topical treatments.

UCB and Biogen report positive Phase III PHOENYCS GO trial results for dapirolizumab pegol in moderate-to-severe SLE, with a second Phase 3 trial, PHOENYCS FLY, planned for 2024. The SLE market is expected to grow from USD 3.2 billion in 2023, driven by emerging therapies like Litifilimab, Ianalumab, and Cenerimod.

Clariant introduces new health care products at CPHI Milan 2024, including VitiPure LEX 3350 S, VitiPure LEX 4000 S, and Polyglykol 1450 S, addressing API delivery and bioavailability challenges. VitiPure Superior line offers nearly colorless, highly-purified excipients for sensitive APIs and low microbial loads, while VitiPure HCO is developed for tablet formulations and topical applications.